The women's health initiative: An unforgettable decade

Menopause

Volumn 19, Issue 6, 2012, Pages 597-599

  Pal, Lubna ^a   Manson, Joann E ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; PLACEBO;

CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; DRUG SAFETY; EDITORIAL; FEMALE; HEART PROTECTION; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL HISTORY; POSTMENOPAUSE; PRESCRIPTION; TREATMENT OUTCOME;

AGED; CONTROLLED CLINICAL TRIALS AS TOPIC; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; WOMEN'S HEALTH;

EID: 84862143430     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e31825397f0     Document Type: Editorial

References (15)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-333.
2. Womens Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291: 1701-1712.
3. American College of Physicians. Guidelines for counseling post-menopausal women about preventive hormone therapy. Ann Intern Med 1992;117: 1038-1041.
4. Jacobs Institute of Women's Health Expert Panel on Menopause Counseling. Guidelines for Counseling Women on the Management of Menopause. Washington, DC: Jacobs Institute of Women's Health, 2000.
5. Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002;53:605-619.
6. The North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2012 position statement of The North American Menopause Society. Menopause 2012;19:257-271.
7. Lukes A. Evolving issues in the clinical and managed care settings on the management of menopause following the Women's Health Initiative. J Manag Care Pharm 2008;14(Suppl):7-13.
8. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-941.
9. Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med 2006;21: 363-366.
10. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007;356:2591-2602.
11. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477.
12. Stram DO, Liu Y, Henderson KD, et al. Age-specific effects of hormone therapy use on overall mortality and ischemic heart disease mortality among women in the California Teachers Study. Menopause 2011;18: 253-261.
13. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
14. Harman SM. Estrogen replacement in menopausal women: recent and current prospective studies, the WHI and the KEEPS [review]. Gend Med 2006;3:254-269.
15. ELITE: Early Versus Late Intervention Trial With Estradiol. Available at: http://clinicaltrials.gov/ct2/show/NCT00114517. Accessed January 6, 2012.